Report Highlights Lower-Risk Companies with Promising Pipelines and Strong Partners

Companies Profiled Include: AEZS AXCA BMRN CVTX LGND MDCO NPSP PTIE SLXP THLD

New York, April 6, 2006 – Revere Data, LLC, a fast-growing provider of independent research data and investment analytics, today announced a new Biotech Pipeline Risk Report that identifies micro- to mid-cap biotechnology companies with promising but relatively low-risk drug development pipelines.

The Biotech Pipeline Risk Report is designed to generate ideas for trading and investment opportunities in the Biopharmaceuticals sector. The Report is available on Revere’s website at www.reveredata.com/reports/store/reporttype?
type=biopipe. For current Revere subscribers, the Biotech Pipeline Risk Report is available in the new Reports section of Revere Research™.

“Often an early-stage biotech company’s future is largely linked to the success or failure of a single drug candidate,” noted Brian Hill, Director of Research for Revere. “Using Revere’s patented classification system and exclusive Revere Relationship data, however, customers can quickly identify companies that have diversified late-stage drug portfolios built around proven technologies.”

Specifically, the latest Biotech Pipeline Risk Report identifies companies that meet all of the following criteria:

1. At least two Phase III or FDA-filed drug candidates
2. One or more drug candidates utilizing a mechanism of action already approved by the FDA in other drugs
3. One or more drug candidates facing two or fewer alternative drugs with the same mechanism of action for the same indication
4. An established strategic partnership with at least one blue-chip biopharmaceutical company
5. Market capitalization between $50 million and $1 billion

“Companies meeting all of these criteria are likely to have lower risk relative to other biotechnology companies with late stage drug candidates,” explained Hill, “but attempting to identify them without Revere would be an extremely daunting task. For example, one of the companies, Ligand Pharmaceuticals Inc. (LGND), currently has 5 Phase III or FDA-filed drugs in its pipeline. 4 of the 5 drugs utilize mechanisms of action shared by drugs already approved by the FDA for other indications. Also, 4 of the 5 drugs, if approved, would face two or fewer competing products in the same drug class for their prescribed indications. Lastly, Ligand has already established research collaboration partnerships with industry leaders such as Pfizer (PFE), GlaxoSmithKline (GSK).”

Revere Data offers clients the flexibility to access its exclusive content through Revere Research, a user-friendly web based platform or Revere Datafeed, data files that can be integrated into research and trading applications as well as algorithms. With either application, users gain access to Revere Data’s intelligent database of U.S publicly traded companies and ADR’s not available through other research providers. Revere Data’s clientele includes sellside agency and proprietary traders, buyside traders, hedge fund managers, portfolio managers, equity analysts, and other professionals at leading financial institutions, along with competitive intelligence, business development, and strategy specialists at major corporations.

About Revere

Revere Data, LLC, provides finance and business professionals with superior data and analytics for companies traded publicly on U.S. exchanges. The Revere Data approach is based on precise product and industry classification and identification of key business relationships. Revere Data’s datafeeds and its research and real-time trading applications feature unique content derived from Revere Data’s own independent research: the Revere Hierarchy™, a patented classification system that provides unmatched detail in specifying a company’s business activities and identifying exact competitors, and Revere Relationships™, a database mapping a company to its key competitors, customers, suppliers, and strategic partners. For more information, please visit www.reveredata.com.